# CART22 Alone or in Combination With huCART19 for ALL

> **NCT03620058** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 23 (actual)

## Conditions studied

- Chemotherapy Resistant Acute Lymphoblastic Leukemia
- Refractory Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** CART22-65s cells
- **BIOLOGICAL:** huCART19 Cells

## Key facts

- **NCT ID:** NCT03620058
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-09-27
- **Primary completion:** 2036-01
- **Final completion:** 2036-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03620058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03620058, "CART22 Alone or in Combination With huCART19 for ALL". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03620058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*